<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837835</url>
  </required_header>
  <id_info>
    <org_study_id>104R04</org_study_id>
    <nct_id>NCT02837835</nct_id>
  </id_info>
  <brief_title>Lung Concentrations of Ceftazidime in Patients With Ventilator-associated Pneumonia</brief_title>
  <acronym>CEFTALC</acronym>
  <official_title>Comparison of Lung Concentrations of Ceftazidime Administered by Continuous Versus Intermittent Infusion in Patients With Ventilator-associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <brief_summary>
    <textblock>
      Ceftazidime is a beta-lactam compound that exerts a time-dependent bactericidal effect.&#xD;
      Numerous arguments are in favor of continuous administration of ceftazidime, both for reasons&#xD;
      of clinical efficacy and to preserve bacteriological mutation. The investigators report a&#xD;
      prospective, single-center, parallel-group, randomized, controlled trial comparing two modes&#xD;
      of administration of ceftazidime, namely, continuous administration (loading dose of 20 mg/kg&#xD;
      of body weight followed by 60 mg/kg/day) versus intermittent administration (20 mg/kg over 30&#xD;
      min every 8 h) in 34 patients with ventilator-associated pneumonia due to Gram-negative&#xD;
      bacilli. The study was performed over 48 h with 13 and 18 assessments of serum ceftazidime in&#xD;
      the continuous-infusion group (group A) and the intermittent-fusion group (group B),&#xD;
      respectively. Bronchoalveolar lavage (BAL) was performed at steady state in both groups at 44&#xD;
      h to determine ceftazidime levels in the epithelial lining fluid. The investigators chose a&#xD;
      predefined threshold of 20 mg/liter for serum concentrations of ceftazidime because of&#xD;
      ecological conditions in our center.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective&#xD;
&#xD;
      The main objective of this study is to show the continuous administration of superiority&#xD;
      ceftazidime versus intermittent administration, in terms of lung tissue concentration of&#xD;
      ceftazidime in mechanically ventilated patients with pneumonia caused by a bacillus gram&#xD;
      negative.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      Trial&#xD;
&#xD;
      Prospective therapeutic trial in parallel groups, controlled, randomized, single center&#xD;
      comparing two methods of administration of ceftazidime (continuous administration by&#xD;
      self-pulsed syringe versus discontinuous administration regimens to 3 injections per 24&#xD;
      hours) in patients with severe pneumonia in mechanically ventilated due to gram negative&#xD;
      bacillus.&#xD;
&#xD;
      Population&#xD;
&#xD;
      Patients will be enrolled in the Intensive Care Unit of the Reims university hospital.&#xD;
&#xD;
      All patients meeting the inclusion criteria and respecting the criteria of non-inclusions&#xD;
      (see below) will be consecutively enrolled in the study after obtaining consent. The&#xD;
      allocation of one of the 2 treatment modality will be made by randomization.&#xD;
&#xD;
      Variables and parameters collected in the study:&#xD;
&#xD;
      In addition to sociodemographic variables, variables for inclusion in the study and judgment&#xD;
      criteria, different blood and urine tests will be collected:&#xD;
&#xD;
        1. Criteria for inclusion and non-inclusion (see above);&#xD;
&#xD;
        2. Outcome:&#xD;
&#xD;
           i) concentration in the cell film ceftazidime;&#xD;
&#xD;
           ii) serum concentration of ceftazidime;&#xD;
&#xD;
           iii) period during which the serum concentration of ceftazidime is higher than 20 mg/l;&#xD;
&#xD;
        3. Socio-demographic variables: Age, Gender;&#xD;
&#xD;
        4. Blood Assays: Blood gas; Blood Urea, créatinimémie and chemistry panel; serum protein;&#xD;
           Complete Blood Count; Beta HCG if women of childbearing age; Liver function tests: AST,&#xD;
           ALT, GGT, bilirubin, alkaline phosphatase;&#xD;
&#xD;
        5. Urinary Assays: Creatinine clearance and urinary electrolytes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lung tissue concentration of ceftazidime</measure>
    <time_frame>up to 44 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>continuous administration of ceftazidime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intermittent administration of ceftazidime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftazidime</intervention_name>
    <description>20 mg/kg of body weight followed by 60 mg/kg/day</description>
    <arm_group_label>continuous administration of ceftazidime</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftazidime</intervention_name>
    <description>20 mg/kg over 30 min every 8 h</description>
    <arm_group_label>intermittent administration of ceftazidime</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age &gt;18 years;&#xD;
&#xD;
          -  Patients hospitalized in the general intensive care unit of the University Hospital of&#xD;
             Reims;&#xD;
&#xD;
          -  Nosocomial pneumonia with Gram-negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight &gt;110 kg;&#xD;
&#xD;
          -  Pregnant or breastfeeding women;&#xD;
&#xD;
          -  Known allergy to beta - lactam antibiotics;&#xD;
&#xD;
          -  Renal impairment: clearance &lt;60 calculated by the Cockcroft and Gault;&#xD;
&#xD;
          -  Known history of pulmonary fibrosis;&#xD;
&#xD;
          -  Patients included in another research protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>France</city>
        <state>Reims</state>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Cousson J, Floch T, Guillard T, Vernet V, Raclot P, Wolak-Thierry A, Jolly D. Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2015 Apr;59(4):1905-9. doi: 10.1128/AAC.04232-14. Epub 2015 Jan 12.</citation>
    <PMID>25583727</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftazidime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

